FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224281014> ?p ?o ?g. }

• W4224281014 abstract "Our objective was to examine whether empirical antimicrobial therapy (EAT) against methicillin-susceptible Staphylococcus aureus bacteremia (MS-SAB) with piperacillin-tazobactam (TZP), cefuroxime or combination therapy with one of these was differentially associated with 7-, 30-, and 90- day all-cause mortality or MS-SAB relapse. A multicenter retrospective cohort study of adults with MS-SAB from 2009 through 2018 was used, and 7-, 30-, 90-day mortality and relapse within 90 days were assessed and expressed as hazard ratio (HR) with a 95% confidence interval (95% CI) using Cox proportional hazard regression analysis. Matching of the two monotherapy groups was performed using propensity score matching. In total, 1158 MS-SAB cases were included and received one of three EAT regimens: TZP (n = 429), cefuroxime (n = 337), or TZP or cefuroxime with one or more additional effective antimicrobial (n = 392). The overall 30-day mortality was 28.0% (25.5 to 30.3%). After adjustment and matching, there was no significant difference in 7-, 30-, or 90-day mortality between the therapy groups. The matched HR of death was 0.81 (95% CI, 0.38 to 1.76) at 7 days, 0.82 (95% CI, 0.47 to 1.46) at 30 days, and 0.81 (95% CI, 0.50 to 1.32) at 90 days for TZP compared with cefuroxime. Adjusted HR of 90-day relapse was insignificant between the three therapy groups: TZP: 1.55 (95% CI, 0.54 to 4.43); combination therapy: 1.73 (95% CI, 0.62 to 4.80) compared to cefuroxime. There was no significant difference in 7-, 30-, or 90-day mortality or relapse between MS-SAB patients treated with empirical TZP or cefuroxime after adjustment and matching of covariables. IMPORTANCE This multicenter retrospective matched cohort study evaluated the effect of empirical antimicrobial therapy on the clinical outcome of methicillin-susceptible Staphylococcus aureus bacteremia (MS-SAB) in >1100 adult patients. To the best of our knowledge, this is the largest study to date evaluating the effect of empirical treatment on the MS-SAB outcome. Importantly, the study found no significant difference in either short- or long-term mortality nor relapse between patients with MS-SAB receiving empirical treatment with cefuroxime or piperacillin-tazobactam. As such, this study provides crucial contemporary data supporting the widespread clinical practice of initiating empirical antimicrobial therapy of sepsis with β-lactam-β-lactamase-inhibitor." @default.
• W4224281014 created "2022-04-26" @default.
• W4224281014 creator A5021492378 @default.
• W4224281014 creator A5042553258 @default.
• W4224281014 creator A5061162624 @default.
• W4224281014 creator A5065648229 @default.
• W4224281014 creator A5077184814 @default.
• W4224281014 creator A5085051687 @default.
• W4224281014 date "2022-06-29" @default.
• W4224281014 modified "2023-09-27" @default.
• W4224281014 title "Comparable Effectiveness of Cefuroxime and Piperacillin-Tazobactam as Empirical Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia" @default.
• W4224281014 cites W1878404532 @default.
• W4224281014 cites W1899878653 @default.
• W4224281014 cites W1973359676 @default.
• W4224281014 cites W1994977184 @default.
• W4224281014 cites W2000445173 @default.
• W4224281014 cites W2052328981 @default.
• W4224281014 cites W2077892577 @default.
• W4224281014 cites W2095171628 @default.
• W4224281014 cites W2102463930 @default.
• W4224281014 cites W2106864992 @default.
• W4224281014 cites W2141436268 @default.
• W4224281014 cites W2161881689 @default.
• W4224281014 cites W2164935114 @default.
• W4224281014 cites W2234641576 @default.
• W4224281014 cites W2327469475 @default.
• W4224281014 cites W2332484561 @default.
• W4224281014 cites W2558519256 @default.
• W4224281014 cites W2742704501 @default.
• W4224281014 cites W2767288214 @default.
• W4224281014 cites W2782616736 @default.
• W4224281014 cites W2888824532 @default.
• W4224281014 cites W2893388489 @default.
• W4224281014 cites W2939413888 @default.
• W4224281014 cites W2944611666 @default.
• W4224281014 cites W2955114250 @default.
• W4224281014 cites W2989769462 @default.
• W4224281014 cites W3016555942 @default.
• W4224281014 doi "https://doi.org/10.1128/spectrum.01530-21" @default.
• W4224281014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35438533" @default.
• W4224281014 hasPublicationYear "2022" @default.
• W4224281014 type Work @default.
• W4224281014 citedByCount "1" @default.
• W4224281014 countsByYear W42242810142023 @default.
• W4224281014 crossrefType "journal-article" @default.
• W4224281014 hasAuthorship W4224281014A5021492378 @default.
• W4224281014 hasAuthorship W4224281014A5042553258 @default.
• W4224281014 hasAuthorship W4224281014A5061162624 @default.
• W4224281014 hasAuthorship W4224281014A5065648229 @default.
• W4224281014 hasAuthorship W4224281014A5077184814 @default.
• W4224281014 hasAuthorship W4224281014A5085051687 @default.
• W4224281014 hasBestOaLocation W42242810141 @default.
• W4224281014 hasConcept C126322002 @default.
• W4224281014 hasConcept C141071460 @default.
• W4224281014 hasConcept C167135981 @default.
• W4224281014 hasConcept C17923572 @default.
• W4224281014 hasConcept C207103383 @default.
• W4224281014 hasConcept C2777052132 @default.
• W4224281014 hasConcept C2777514703 @default.
• W4224281014 hasConcept C2777637488 @default.
• W4224281014 hasConcept C2777858937 @default.
• W4224281014 hasConcept C2778193466 @default.
• W4224281014 hasConcept C2778266534 @default.
• W4224281014 hasConcept C2779443120 @default.
• W4224281014 hasConcept C2779489039 @default.
• W4224281014 hasConcept C2779631663 @default.
• W4224281014 hasConcept C3019249092 @default.
• W4224281014 hasConcept C44249647 @default.
• W4224281014 hasConcept C501593827 @default.
• W4224281014 hasConcept C50382708 @default.
• W4224281014 hasConcept C523546767 @default.
• W4224281014 hasConcept C54355233 @default.
• W4224281014 hasConcept C71924100 @default.
• W4224281014 hasConcept C86803240 @default.
• W4224281014 hasConcept C89423630 @default.
• W4224281014 hasConcept C94665300 @default.
• W4224281014 hasConceptScore W4224281014C126322002 @default.
• W4224281014 hasConceptScore W4224281014C141071460 @default.
• W4224281014 hasConceptScore W4224281014C167135981 @default.
• W4224281014 hasConceptScore W4224281014C17923572 @default.
• W4224281014 hasConceptScore W4224281014C207103383 @default.
• W4224281014 hasConceptScore W4224281014C2777052132 @default.
• W4224281014 hasConceptScore W4224281014C2777514703 @default.
• W4224281014 hasConceptScore W4224281014C2777637488 @default.
• W4224281014 hasConceptScore W4224281014C2777858937 @default.
• W4224281014 hasConceptScore W4224281014C2778193466 @default.
• W4224281014 hasConceptScore W4224281014C2778266534 @default.
• W4224281014 hasConceptScore W4224281014C2779443120 @default.
• W4224281014 hasConceptScore W4224281014C2779489039 @default.
• W4224281014 hasConceptScore W4224281014C2779631663 @default.
• W4224281014 hasConceptScore W4224281014C3019249092 @default.
• W4224281014 hasConceptScore W4224281014C44249647 @default.
• W4224281014 hasConceptScore W4224281014C501593827 @default.
• W4224281014 hasConceptScore W4224281014C50382708 @default.
• W4224281014 hasConceptScore W4224281014C523546767 @default.
• W4224281014 hasConceptScore W4224281014C54355233 @default.
• W4224281014 hasConceptScore W4224281014C71924100 @default.
• W4224281014 hasConceptScore W4224281014C86803240 @default.
• W4224281014 hasConceptScore W4224281014C89423630 @default.
• W4224281014 hasConceptScore W4224281014C94665300 @default.

• next